OMass Therapeutics

#Endocrinology #Financing #Immunology #OMass Therapeutics

OMass closes $310m oversubscribed financing round

Biotechnology company OMass Therapeutics has raised $310 million as part of an oversubscribed Series C financing round.  The funding will be used to support the advancement of the company’s lead programme into Phase II clinical development.   The company’s lead compound, OMS1620, is a potential best-in-class MC2 (melanocortin-2) receptor antagonist targeting congenital… Read More

#Business & Investment #News